Health
ACE2 agonist C21 relieves respiratory difficulty in COVID-19 – News-Medical.Net
A new study describes a pilot study on the efficacy of a molecule called C21, which enhances the activity of the angiotensin-converting enzyme 2 (ACE2), the host…
The advent of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to over 2.2 million deaths over a period of just over a year. The lack of effective drugs to combat the virus has led to intensive research to identify preventive and therapeutic antivirals.
A new preprint on the medRxiv* server describes a pilot study on the efficacy of a molecule called C21, which enhances the activity of the angiotensin-converting…
-
Noosa News23 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News22 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
Business9 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General18 hours ago‘Potential’ hacker contacts Qantas over data breach